Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2014

Open Access 01-12-2014 | Research

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms

Authors: Zhiyuan Wu, Xinju Zhang, Xiao Xu, Yuming Chen, Tingting Hu, Zhihua Kang, Shibao Li, Hua Wang, Weiwei Liu, Xiaochao Ma, Ming Guan

Published in: Journal of Hematology & Oncology | Issue 1/2014

Login to get access

Abstract

Mutations in JAK2, MPL and CALR are highly relevant to the Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs). We performed high resolution melting analysis and Sanger sequencing together with T-A cloning to elucidate the unique mutation profile of these genes, in Chinese patients with MPNs. Peripheral blood DNA samples were obtained from 80 patients with polycythemia vera (PV), 80 patients with essential thrombocytosis (ET) and 50 patients with primary myelofibrosis (PMF). Ten PV patients were identified with diverse JAK2 exon 12 mutations. Five novel JAK2 Exon 12 mutation patterns (M532V/E543G, N533D, M535I/H538Y/K549I, E543G and D544N) were described. JAK2 V617F was detected in 140 samples (66 PV, 45 ET and 29 PMF). JAK2 Exon 12 mutations were prevalent (13%) and variable in the Chinese patients. Compared with PV patients with JAK2 V617F mutations, PV patients with JAK2 exon 12 mutations had an earlier median onset of disease (P = 0.0013). MPL W515L/K mutations were discerned in 4 ET and 3 PMF patients. Two kinds of CALR mutation, c. 1179_1230del and c. 1234_1235insTTGTC were detected in 20 ET and 16 PMF patients. A novel CALR mutation pattern (c. 1173_1223del/c. 1179_1230del) was identified in 2 PMF samples. In addition, 17 scattered point mutations in CALR c.1153 to c.1255 were also detected in 13 cases with CALR frame-shifting variations and 2 cases without CALR frame-shifting variations. Female patients showed a predisposition to CALR mutations (P = 0.0035). Chinese Ph-negative MPN patients have a unique mutation landscape in the common molecular markers of MPN diagnosis. Validation of the molecular diagnostic pipeline should be emphasized since there is a considerable ethnical diversity in the molecular profiles of Ph-negative MPNs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dameshek W: Editorial: some speculations on the myeloproliferative syndromes. Blood. 1951, 6: 372-375.PubMed Dameshek W: Editorial: some speculations on the myeloproliferative syndromes. Blood. 1951, 6: 372-375.PubMed
2.
go back to reference Nowell PC: A minute chromosome in human chronic granulocytic leukemia. Science. 1960, 132: 1497. Nowell PC: A minute chromosome in human chronic granulocytic leukemia. Science. 1960, 132: 1497.
3.
go back to reference Swerdllow S, Campo E, Harris NL: Who Classification Of Tumours Of Haematopoietic And Lymphoid Tissues. 2008, IARC Press, France Swerdllow S, Campo E, Harris NL: Who Classification Of Tumours Of Haematopoietic And Lymphoid Tissues. 2008, IARC Press, France
4.
go back to reference Lewis SM, Bain BJ, Bates I, Dacie JV: Dacie And Lewis Practical Haematology. 2006, Elsevier Health Sciences, Philadelphia Lewis SM, Bain BJ, Bates I, Dacie JV: Dacie And Lewis Practical Haematology. 2006, Elsevier Health Sciences, Philadelphia
5.
go back to reference James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434: 1144-1148. 10.1038/nature03546.CrossRefPubMed James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005, 434: 1144-1148. 10.1038/nature03546.CrossRefPubMed
6.
go back to reference Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365: 1054-1061. 10.1016/S0140-6736(05)71142-9.CrossRefPubMed Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365: 1054-1061. 10.1016/S0140-6736(05)71142-9.CrossRefPubMed
7.
go back to reference Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007, 356: 459-468. 10.1056/NEJMoa065202.PubMedCentralCrossRefPubMed Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007, 356: 459-468. 10.1056/NEJMoa065202.PubMedCentralCrossRefPubMed
8.
go back to reference Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3: e270-10.1371/journal.pmed.0030270.PubMedCentralCrossRefPubMed Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3: e270-10.1371/journal.pmed.0030270.PubMedCentralCrossRefPubMed
9.
go back to reference Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006, 108: 3472-3476. 10.1182/blood-2006-04-018879.CrossRefPubMed Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006, 108: 3472-3476. 10.1182/blood-2006-04-018879.CrossRefPubMed
10.
go back to reference Tefferi A, Vardiman J: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008, 22: 14-22. 10.1038/sj.leu.2404955.CrossRefPubMed Tefferi A, Vardiman J: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008, 22: 14-22. 10.1038/sj.leu.2404955.CrossRefPubMed
11.
go back to reference Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013, 369: 2379-2390. 10.1056/NEJMoa1311347.CrossRefPubMed Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013, 369: 2379-2390. 10.1056/NEJMoa1311347.CrossRefPubMed
12.
go back to reference Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013, 369: 2391-2405. 10.1056/NEJMoa1312542.PubMedCentralCrossRefPubMed Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013, 369: 2391-2405. 10.1056/NEJMoa1312542.PubMedCentralCrossRefPubMed
13.
go back to reference Tefferi A, Thiele J, Vannucchi A, Barbui T: An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014, ᅟ: ᅟ-[Epub ahead of print] Tefferi A, Thiele J, Vannucchi A, Barbui T: An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014, ᅟ: ᅟ-[Epub ahead of print]
14.
go back to reference Tefferi A, Pardanani A: Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol. 2014, 11: 125-126. 10.1038/nrclinonc.2014.16.CrossRefPubMed Tefferi A, Pardanani A: Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol. 2014, 11: 125-126. 10.1038/nrclinonc.2014.16.CrossRefPubMed
15.
go back to reference Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397. 10.1016/j.ccr.2005.03.023.CrossRefPubMed Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397. 10.1016/j.ccr.2005.03.023.CrossRefPubMed
16.
go back to reference Jones AV, Cross NC, White HE, Green AR, Scott LM: Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica. 2008, 93: 1560-1564. 10.3324/haematol.12883.CrossRefPubMed Jones AV, Cross NC, White HE, Green AR, Scott LM: Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica. 2008, 93: 1560-1564. 10.3324/haematol.12883.CrossRefPubMed
17.
go back to reference Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, Buser AS, Gratwohl A, Tichelli A, Skoda RC: The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008, 93: 1890-1893. 10.3324/haematol.13074.CrossRefPubMed Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, Buser AS, Gratwohl A, Tichelli A, Skoda RC: The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008, 93: 1890-1893. 10.3324/haematol.13074.CrossRefPubMed
18.
go back to reference Wu Z, Yuan H, Zhang X, Liu W, Xu J, Zhang W, Guan M: Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS One. 2011, 6: e26534-10.1371/journal.pone.0026534.PubMedCentralCrossRefPubMed Wu Z, Yuan H, Zhang X, Liu W, Xu J, Zhang W, Guan M: Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS One. 2011, 6: e26534-10.1371/journal.pone.0026534.PubMedCentralCrossRefPubMed
19.
go back to reference Pancrazzi A, Guglielmelli P, Ponziani V, Bergamaschi G, Bosi A, Barosi G, Vannucchi AM: A sensitive detection method for MPL W515L or MPL W515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008, 10: 435-441. 10.2353/jmoldx.2008.080015.PubMedCentralCrossRefPubMed Pancrazzi A, Guglielmelli P, Ponziani V, Bergamaschi G, Bosi A, Barosi G, Vannucchi AM: A sensitive detection method for MPL W515L or MPL W515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008, 10: 435-441. 10.2353/jmoldx.2008.080015.PubMedCentralCrossRefPubMed
20.
go back to reference Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L: Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008, 111: 1686-1689. 10.1182/blood-2007-07-101576.CrossRefPubMed Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L: Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008, 111: 1686-1689. 10.1182/blood-2007-07-101576.CrossRefPubMed
21.
go back to reference Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F: Characteristics and clinical correlates of MPL 515W> L/K mutation in essential thrombocythemia. Blood. 2008, 112: 844-847. 10.1182/blood-2008-01-135897.CrossRefPubMed Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F: Characteristics and clinical correlates of MPL 515W> L/K mutation in essential thrombocythemia. Blood. 2008, 112: 844-847. 10.1182/blood-2008-01-135897.CrossRefPubMed
22.
go back to reference Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R: MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008, 112: 141-149. 10.1182/blood-2008-01-131664.CrossRefPubMed Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R: MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008, 112: 141-149. 10.1182/blood-2008-01-131664.CrossRefPubMed
23.
go back to reference Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupré N, Skoda RC, Hermouet S: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006, 108: 1865-1867. 10.1182/blood-2006-01-013540.CrossRefPubMed Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupré N, Skoda RC, Hermouet S: The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006, 108: 1865-1867. 10.1182/blood-2006-01-013540.CrossRefPubMed
24.
go back to reference Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S: A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010, 24: 1574-1579. 10.1038/leu.2010.148.CrossRefPubMed Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S: A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010, 24: 1574-1579. 10.1038/leu.2010.148.CrossRefPubMed
25.
go back to reference Pardanani A, Lasho T, Finke C, Hanson C, Tefferi A: Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007, 21: 1960-1963. 10.1038/sj.leu.2404810.CrossRefPubMed Pardanani A, Lasho T, Finke C, Hanson C, Tefferi A: Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007, 21: 1960-1963. 10.1038/sj.leu.2404810.CrossRefPubMed
26.
go back to reference Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian J-J, McMullin MF, Ruggeri M, Besses C: Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011, 117: 2813-2816. 10.1182/blood-2010-11-316810.CrossRefPubMed Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian J-J, McMullin MF, Ruggeri M, Besses C: Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011, 117: 2813-2816. 10.1182/blood-2010-11-316810.CrossRefPubMed
27.
go back to reference Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G: JAK2 V617F and Exon 12 Genetic Variations in Korean Patients with BCR/ABL1-negative Myeloproliferative Neoplasms. Korean J Lab Med. 2010, 30: 567-574. 10.3343/kjlm.2010.30.6.567.CrossRefPubMed Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G: JAK2 V617F and Exon 12 Genetic Variations in Korean Patients with BCR/ABL1-negative Myeloproliferative Neoplasms. Korean J Lab Med. 2010, 30: 567-574. 10.3343/kjlm.2010.30.6.567.CrossRefPubMed
28.
go back to reference Ohyashiki JH, Hisatomi H, Shimizu S, Sugaya M, Ohyashiki K: Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis. Jpn J Clin Oncol. 2009, 39: 509-513. 10.1093/jjco/hyp048.CrossRefPubMed Ohyashiki JH, Hisatomi H, Shimizu S, Sugaya M, Ohyashiki K: Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis. Jpn J Clin Oncol. 2009, 39: 509-513. 10.1093/jjco/hyp048.CrossRefPubMed
29.
go back to reference Yeh Y-M, Chen Y-L, Cheng H-Y, Su W-C, Chow N-H, Chen T-Y, Ho C-L: High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. Am J Clin Pathol. 2010, 134: 266-270. 10.1309/AJCPK7KGOWPHYWM0.CrossRefPubMed Yeh Y-M, Chen Y-L, Cheng H-Y, Su W-C, Chow N-H, Chen T-Y, Ho C-L: High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. Am J Clin Pathol. 2010, 134: 266-270. 10.1309/AJCPK7KGOWPHYWM0.CrossRefPubMed
30.
go back to reference Schnittger S, Bacher U, Haferlach C, Geer T, Müller P, Mittermüller J, Petrides P, Schlag R, Sandner R, Selbach J: Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica. 2009, 94: 414-418. 10.3324/haematol.13223.PubMedCentralCrossRefPubMed Schnittger S, Bacher U, Haferlach C, Geer T, Müller P, Mittermüller J, Petrides P, Schlag R, Sandner R, Selbach J: Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica. 2009, 94: 414-418. 10.3324/haematol.13223.PubMedCentralCrossRefPubMed
31.
go back to reference Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C: CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014, 123: 2416-2419. 10.1182/blood-2014-01-550434.CrossRefPubMed Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C: CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014, 123: 2416-2419. 10.1182/blood-2014-01-550434.CrossRefPubMed
32.
go back to reference Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M: Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014, 123: 2220-2228. 10.1182/blood-2013-11-537167.CrossRefPubMed Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M: Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014, 123: 2220-2228. 10.1182/blood-2013-11-537167.CrossRefPubMed
33.
go back to reference Tefferi A, Pardanani A, Lim K, Abdel-Wahab O, Lasho T, Patel J, Gangat N, Finke C, Schwager S, Mullally A: TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009, 23: 905-911. 10.1038/leu.2009.47.PubMedCentralCrossRefPubMed Tefferi A, Pardanani A, Lim K, Abdel-Wahab O, Lasho T, Patel J, Gangat N, Finke C, Schwager S, Mullally A: TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009, 23: 905-911. 10.1038/leu.2009.47.PubMedCentralCrossRefPubMed
34.
go back to reference Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010, 24: 1128-1138. 10.1038/leu.2010.69.PubMedCentralCrossRefPubMed Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010, 24: 1128-1138. 10.1038/leu.2010.69.PubMedCentralCrossRefPubMed
35.
go back to reference Stegelmann F, Bullinger L, Schlenk R, Paschka P, Griesshammer M, Blersch C, Kuhn S, Schauer S, Döhner H, Döhner K: DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011, 25: 1217-1219. 10.1038/leu.2011.77.CrossRefPubMed Stegelmann F, Bullinger L, Schlenk R, Paschka P, Griesshammer M, Blersch C, Kuhn S, Schauer S, Döhner H, Döhner K: DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011, 25: 1217-1219. 10.1038/leu.2011.77.CrossRefPubMed
36.
go back to reference Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi‐Boyer V, Arnoulet C, Gisserot O: Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012, 51: 743-755. 10.1002/gcc.21960.CrossRefPubMed Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi‐Boyer V, Arnoulet C, Gisserot O: Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012, 51: 743-755. 10.1002/gcc.21960.CrossRefPubMed
37.
go back to reference Vorechovsky I, Jones A, Cross N: Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms&quest. Leukemia. 2013, 27: 1930-1932. 10.1038/leu.2013.85.CrossRefPubMed Vorechovsky I, Jones A, Cross N: Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms&quest. Leukemia. 2013, 27: 1930-1932. 10.1038/leu.2013.85.CrossRefPubMed
38.
go back to reference Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM: Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014, 123: 1552-1555.CrossRefPubMed Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM: Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014, 123: 1552-1555.CrossRefPubMed
39.
go back to reference Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014, 123: 1544-1551. 10.1182/blood-2014-01-550434.PubMedCentralCrossRefPubMed Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014, 123: 1544-1551. 10.1182/blood-2014-01-550434.PubMedCentralCrossRefPubMed
40.
go back to reference Tefferi A, Wassie E, Lasho T, Finke C, Belachew A, Ketterling R, Hanson C, Pardanani A, Gangat N, Wolanskyj A: Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014, ᅟ: ᅟ-[Epub ahead of print] Tefferi A, Wassie E, Lasho T, Finke C, Belachew A, Ketterling R, Hanson C, Pardanani A, Gangat N, Wolanskyj A: Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014, ᅟ: ᅟ-[Epub ahead of print]
41.
go back to reference Gianelli U, Iurlo A, Cattaneo D, Lambertenghi-Deliliers G: Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Expert Rev Hematol. 2014, 7: 255-264. 10.1586/17474086.2014.876898.CrossRefPubMed Gianelli U, Iurlo A, Cattaneo D, Lambertenghi-Deliliers G: Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Expert Rev Hematol. 2014, 7: 255-264. 10.1586/17474086.2014.876898.CrossRefPubMed
Metadata
Title
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
Authors
Zhiyuan Wu
Xinju Zhang
Xiao Xu
Yuming Chen
Tingting Hu
Zhihua Kang
Shibao Li
Hua Wang
Weiwei Liu
Xiaochao Ma
Ming Guan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2014
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-014-0048-6

Other articles of this Issue 1/2014

Journal of Hematology & Oncology 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine